Influence of age on incident diabetes (DM) and cardiovascular disease (CVD) among prostate cancer survivors receiving androgen deprivation therapy (ADT).

Alicia K. Morgans(Dana-Farber Cancer Institute), David F. Penson(Geriatric Research Education and Clinical Center), Peter C. Albertsen(UConn Health), Richard M. Hoffman(University of Iowa), Tatsuki Koyama(Vanderbilt University Medical Center), Janet L. Stanford, Daniel A. Barocas(Vanderbilt University Medical Center), Christina Louise Derleth, Ann S. Hamilton(University of Southern California), Kang-Hsien Fan, Antoinette M. Stroup(Rutgers, The State University of New Jersey), Matthew J. Resnick(Vanderbilt University Medical Center), Michael Goodman(Emory University)
Journal of Clinical Oncology
May 20, 2014
10.1200/jco.2014.32.15_suppl.6583
Cited by 0

Related Papers

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779